The plasma levels of TROP2, TSPAN6, BST2, and NGFR in CRC patients and healthy controls were determined to be 48.88 ± 3.00 ng/mL versus 63.05 ± 5.61 ng/mL (p = 0.02), 68.15 ± 1.02 pg/mL versus 65.02 ± 0.01 pg/mL (p < 0.01), 2.23 ± 0.20 ng/mL versus 1.13 ± 0.06 ng/mL (p < 0.01), and 140.00 ± 3.85 pg/mL versus 314.40 ± 137.00 pg/mL (p = 0.20), respectively (Figure 1(a)). Here, TACSTD2 is linked to colorectal carcinoma.